Drug Trial Radar · NCT07184619
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jan 23, 2026
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Newron Pharmaceuticals SPAIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.
Conditions
- Treatment-resistant Schizophrenia
Interventions
Evenamide 15 mg bidDrug
Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment
PlaceboDrug
Matching placebo capsules bid for a total of 12 weeks of add-on treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to endpoint (Week 12) on the total score of the Positive and Negative Syndrome Scale (PANSS).Time frame: From Baseline to Week 12
- Incidence of treatment-emergent adverse events (TEAEs), AEs leading to discontinuation (ADOs), and serious AEs (SAEs).Time frame: From Baseline to 30-day Safety Follow up (12 Weeks of treament + 30-day safety follow up)
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
UCLA DGSOM, UCLA Health, UCLA Semel Institute
Los Angeles, California · Suspended
University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital
Miami, Florida · Suspended
Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine
Atlanta, Georgia · Suspended
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
Baltimore, Maryland · Suspended
Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research
New York, New York · Suspended
INSA- Instituto de Neurociencias San Agustin
La Plata, Buenos Aires, Argentina · Recruiting
Global Psy Asociacion Civil
La Plata, Buenos Aires, Argentina · Not yet recruiting
Fundación para el Estudio y Tratamiento de las Enfermedades Mentales
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Centro Iternova-Consultorios en Salud Mental
Córdoba, Córdoba Province, Argentina · Not yet recruiting
Centro Especializado en Neurociencias (CEN)
Córdoba, Córdoba Province, Argentina · Recruiting
Fundacion Estudios Clinicos
Rosario, Santa Fe Province, Argentina · Not yet recruiting
CIAP-Centro de Invest y Asistencia en Psiquiatria
Rosario, Santa Fe Province, Argentina · Recruiting
E.S.E. Hosp Mental de Antioquia Maria Upegui-Homo
Bello, Antioquia, Colombia · Not yet recruiting
Inst Colombiano del Sistema Nervioso - ClinMontserrat
Bogotá, Bogota D.C., Colombia · Not yet recruiting
Help Hospital
Vijayawada, Andhra Pradesh, India · Recruiting
Gauhati Medical College and Hospital
Guwahati, Assam, India · Recruiting
Masina Hospital Trust
Mumbai, Maharashtra, India · Recruiting
New Manak Healthcare Hospital
Navi Mumbai, Maharashtra, India · Recruiting
Ahana Hospitals LLP
Madurai, Tamil Nadu, India · Recruiting
Udyan Health Care
Lucknow, Uttar Pradesh, India · Recruiting
Seth Sukhlal Karnani Memorial Hospital
Kolkata, West Bengal, India · Recruiting
Hospital Tuanku Fauziah
Kangar, Malaysia · Recruiting
Sentosa Hospital
Kuching, Malaysia · Recruiting
Sultan Abdul Halim Hospital
Sungai Petani, Malaysia · Recruiting
Kuala Lumpur Hospital
Kuala Lumpur, Kuala Lumpur, Malaysia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.